ReviewPflugers Archiv : European journal of physiology2026
The effects of elevated phosphate on the kidney - damaging the gatekeeper.
Review in Pflugers Archiv : European journal of physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Planetary Health Diet: Emphasizing Nutritional Therapy in Kidney Disease.Clinical journal of the American Society of Nephrology : CJASN · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The kidney is a major regulator of phosphate metabolism. The body can lower systemic phosphate levels by increasing renal phosphate excretion, and kidney injury results in elevated serum phosphate concentrations (hyperphosphatemia). Chronic kidney disease (CKD) is associated with various organ injuries, including vascular calcification and cardiovascular disease, where hyperphosphatemia acts as a pathologic driver. Here we discuss hyperphosphatemia not as a consequence of kidney disease but as a potential contributor to kidney damage. We describe how increases in renal tubular phosphate levels (hyperphosphaturia), rather than hyperphosphatemia contribute to kidney injury in CKD. Tubular phosphate can form microcrystals with calcium which damages renal epithelial cells, induces fibrosis and inflammation, and causes parenchymal calcification. Calcium phosphate microcrystals can grow and form larger deposits in the renal collecting system, and potentially contribute to the formation of kidney stones. Therefore, hyperphosphaturia might not only contribute to kidney damage in CKD, but could also cause kidney injury in genetic diseases with reduced renal phosphate uptake. Finally, since high dietary phosphate intake increases renal phosphate excretion, we discuss if prolonged phosphate loading in the absence of CKD can induce kidney damage. We propose that a better understanding of the pathologic actions of phosphate on the kidney will help to identify novel therapeutic strategies to prevent renal injury and disease progression in patients with CKD and in other renal conditions, such as kidney stone formation. Lowering dietary phosphate intake might not only have reno-protective effects in patients with pre-existing kidney damage but also in healthy individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.